Overview
In the field of diagnosing Thrombi diseases, it is now a well established practice to inject positron-emitting tracers into the human body.
These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own GPIIb/IIIa imaging agents.
Description
This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F/68Ga\]GP1 PET imaging. \[18F/68Ga\]GP1 is a small molcule-based tracer that offers stronger binding affinity to GPIIb/IIIa. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F/68Ga\]GP1 PET imaging in human subjects.
Eligibility
Inclusion Criteria:
- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated thrombi (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled GPIIb/IIIa PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria:
- (i) patients with non-thrombi lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
